urea has been researched along with Myocardial Ischemia in 21 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We assessed two suggested new inotropic strategies in a clinically relevant pig model of ischemic acute heart failure (AHF): treatment with the myosin activator omecamtiv mecarbil (OM) or dobutamine and ivabradine (D+I)." | 7.88 | Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure. ( Bakkehaug, JP; How, OJ; Kildal, AB; Myrmel, T; Rødland, L; Rønning, L, 2018) |
| " Therefore, in order to control the heart rate and prevent myocardial ischemia, low dose landiolol was infused prophylactically." | 7.74 | [Landiolol prevented myocardial ischemia in a patient with severe aortic stenosis undergoing total gastrectomy]. ( Nakagawa, H; Nanba, M; Okayama, Y, 2007) |
| "Landiolol, a highly cardioselective beta1-blocker, has cardioprotective effects against ischemia-reperfusion injury, although the precise mechanism is still unclear." | 7.74 | Landiolol has cardioprotective effects against reperfusion injury in the rat heart via the PKCepsilon signaling pathway. ( Hirai, H; Minamiyama, Y; Sakaguchi, M; Sasaki, Y; Shibata, T; Suehiro, S; Takahashi, Y; Takemura, S, 2007) |
| " We assessed two suggested new inotropic strategies in a clinically relevant pig model of ischemic acute heart failure (AHF): treatment with the myosin activator omecamtiv mecarbil (OM) or dobutamine and ivabradine (D+I)." | 3.88 | Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure. ( Bakkehaug, JP; How, OJ; Kildal, AB; Myrmel, T; Rødland, L; Rønning, L, 2018) |
| " Therefore, in order to control the heart rate and prevent myocardial ischemia, low dose landiolol was infused prophylactically." | 3.74 | [Landiolol prevented myocardial ischemia in a patient with severe aortic stenosis undergoing total gastrectomy]. ( Nakagawa, H; Nanba, M; Okayama, Y, 2007) |
| "Landiolol, a highly cardioselective beta1-blocker, has cardioprotective effects against ischemia-reperfusion injury, although the precise mechanism is still unclear." | 3.74 | Landiolol has cardioprotective effects against reperfusion injury in the rat heart via the PKCepsilon signaling pathway. ( Hirai, H; Minamiyama, Y; Sakaguchi, M; Sasaki, Y; Shibata, T; Suehiro, S; Takahashi, Y; Takemura, S, 2007) |
| "Omecamtiv mecarbil is a selective cardiac myosin activator that augments cardiac contractility in patients with systolic heart failure through a dose-dependent increase in systolic ejection time." | 2.80 | Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. ( Chen, MM; Chou, W; Eisenberg, P; Escandón, R; Greenberg, BH; Lee, JH; Malik, FI; Megreladze, I; Saikali, KG; Shaburishvili, T; Treshkur, T; Wasserman, SM; Wolff, AA, 2015) |
| "Landiolol hydrochloride was confirmed to reduce heart rate significantly and rapidly after intravenous injection and this suggests that the study drug is a safe and useful agent for improving the image quality of CCTA by 16-slice MDCT." | 2.79 | A multicenter, open-label study of an intravenous short-acting β1-adrenergic receptor antagonist landiolol hydrochloride for coronary computed tomography angiography by 16-slice multi-detector computed tomography in Japanese patients with suspected ischem ( Hara, K; Hirano, M; Iino, M; Ikari, Y; Jinzaki, M; Kuribayashi, S; Tanimoto, M; Yamaguchi, T; Yamashina, A, 2014) |
| "Landiolol hydrochloride is an intravenous β1-blocker with a very short half-life." | 2.78 | Dose-finding study of landiolol hydrochloride: a short-acting β1-blocker for controlling heart rate during coronary computed-tomography angiography in Japan. ( Hamada, C; Hara, K; Hirano, M; Iino, M; Ikari, Y; Jinzaki, M; Kuribayashi, S, 2013) |
| "Esmolol also has been used for treatment of perioperative hypertension and for reducing cardiac work in patients with ischemic heart disease." | 2.43 | [New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system]. ( Mio, Y, 2006) |
| "In male rats, acute renal failure was simulated by clamping the vascular pedicle of the left kidney for 60 or 90 min and right-sided nephrectomy." | 1.56 | Stimulation of Structural and Functional Recovery of the Kidney in Rats with Postischemic Acute Renal Failure of Different Severity by Embryonic Protein-Peptide Complex Therapy. ( Drozhzheva, VV; Efremov, GD; Golovanov, SA; Kirpatovskii, VI; Samoilova, SI; Sivkov, AV, 2020) |
| "Ischemic arrhythmias are the main causes of sudden cardiac death." | 1.46 | Soluble epoxide hydrolase inhibitors might prevent ischemic arrhythmias via microRNA-1 repression in primary neonatal mouse ventricular myocytes. ( Gui, YJ; Liao, CX; Liu, Q; Peng, R; Wang, M; Xu, DY; Zhao, W; Zhao, X, 2017) |
| "Landiolol is a short-acting beta-blocker, with high beta 1-selectivity and a short duration of action." | 1.35 | Clinical role and efficacy of landiolol in the intensive care unit. ( Akada, S; Hongo, T; Miyagi, Y; Sakamoto, A; Sato, C; Takeda, S; Tanaka, K; Terajima, K; Yoshida, Y, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Rødland, L | 2 |
| Rønning, L | 2 |
| Kildal, AB | 2 |
| Myrmel, T | 2 |
| How, OJ | 2 |
| Kirpatovskii, VI | 1 |
| Sivkov, AV | 1 |
| Golovanov, SA | 1 |
| Drozhzheva, VV | 1 |
| Efremov, GD | 1 |
| Samoilova, SI | 1 |
| Poveda-Jaramillo, R | 1 |
| Monaco, F | 1 |
| Zangrillo, A | 1 |
| Landoni, G | 1 |
| Bakkehaug, JP | 1 |
| Jinzaki, M | 4 |
| Hirano, M | 4 |
| Hara, K | 3 |
| Suzuki, T | 1 |
| Yamashina, A | 2 |
| Ikari, Y | 3 |
| Iino, M | 3 |
| Yamaguchi, T | 2 |
| Kuribayashi, S | 4 |
| Hamada, C | 1 |
| Furuichi, Y | 1 |
| Sakamoto, A | 2 |
| Tanimoto, M | 1 |
| Greenberg, BH | 1 |
| Chou, W | 1 |
| Saikali, KG | 1 |
| Escandón, R | 1 |
| Lee, JH | 1 |
| Chen, MM | 1 |
| Treshkur, T | 1 |
| Megreladze, I | 1 |
| Wasserman, SM | 1 |
| Eisenberg, P | 1 |
| Malik, FI | 1 |
| Wolff, AA | 1 |
| Shaburishvili, T | 1 |
| Kido, T | 2 |
| Mochizuki, T | 1 |
| Yamada, Y | 1 |
| Tanaka, R | 1 |
| Kanzaki, S | 1 |
| Higashi, M | 1 |
| Yoshioka, K | 1 |
| Liu, Q | 1 |
| Zhao, X | 1 |
| Peng, R | 1 |
| Wang, M | 1 |
| Zhao, W | 1 |
| Gui, YJ | 1 |
| Liao, CX | 1 |
| Xu, DY | 1 |
| Suzuki, Y | 1 |
| Morihara, A | 1 |
| Desaki, Y | 1 |
| Terao, K | 1 |
| Semba, K | 1 |
| Takasaki, Y | 1 |
| Jindrich, S | 1 |
| Ondrej, L | 1 |
| Viktor, M | 1 |
| Zbynek, P | 1 |
| Tomas, P | 1 |
| Ladislav, D | 1 |
| Jiri, V | 1 |
| Lenka, S | 1 |
| Miroslav, S | 1 |
| Mantovani, V | 1 |
| Kennergren, C | 1 |
| Bugge, M | 1 |
| Sala, A | 1 |
| Lönnroth, P | 1 |
| Berglin, E | 1 |
| Makhneva, AV | 1 |
| Sviridkina, LP | 1 |
| Toporova, SG | 1 |
| Schroeder, MA | 1 |
| Clarke, K | 1 |
| Neubauer, S | 1 |
| Tyler, DJ | 1 |
| Mio, Y | 1 |
| Nakagawa, H | 1 |
| Nanba, M | 1 |
| Okayama, Y | 1 |
| Takahashi, Y | 1 |
| Takemura, S | 1 |
| Minamiyama, Y | 1 |
| Shibata, T | 1 |
| Hirai, H | 1 |
| Sasaki, Y | 1 |
| Sakaguchi, M | 1 |
| Suehiro, S | 1 |
| Yoshida, Y | 1 |
| Terajima, K | 1 |
| Sato, C | 1 |
| Akada, S | 1 |
| Miyagi, Y | 1 |
| Hongo, T | 1 |
| Takeda, S | 1 |
| Tanaka, K | 1 |
| Palmer, A | 1 |
| Bulpitt, C | 1 |
| Beevers, G | 1 |
| Coles, E | 1 |
| Fletcher, A | 1 |
| Ledingham, J | 1 |
| Petrie, J | 1 |
| Webster, J | 1 |
| Dollery, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of ONO-1101 in Patients Scheduled for Coronary Angiography, a Double-Blind, Randomized,Placebo-Controlled, Parallel Group, Multi-Center Study[NCT00560209] | Phase 2 | 183 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina[NCT00682565] | Phase 2 | 94 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00682565)
Timeframe: 1 day
| Intervention | seconds (Mean) |
|---|---|
| Mid Dose Active Drug | 41.5 |
| High Dose Active Drug | 40.5 |
| All Placebo | 60.1 |
"This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B.~Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina." (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 0 |
| High Dose Active Drug | 7 |
| All Placebo | 2 |
The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing. (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 4 |
| High Dose Active Drug | 2 |
| All Placebo | 1 |
The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing. (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 0 |
| High Dose Active Drug | 0 |
| All Placebo | 1 |
ST Segment Depression measured by Electrocardiography while performing ETT-3. (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 0 |
| High Dose Active Drug | 1 |
| All Placebo | 2 |
4 reviews available for urea and Myocardial Ischemia
| Article | Year |
|---|---|
Ultra-Short-Acting β-Blockers (Esmolol and Landiolol) in the Perioperative Period and in Critically Ill Patients.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Cardiac S | 2018 |
[Perioperative cardiovascular evaluation and management for noncardiac surgery].
Topics: Adrenergic beta-Antagonists; Anesthesia; Atenolol; Bisoprolol; Fatty Acids, Monounsaturated; Fluvast | 2014 |
Hyperpolarized magnetic resonance: a novel technique for the in vivo assessment of cardiovascular disease.
Topics: Animals; Bicarbonates; Carbon Isotopes; Cardiomyopathies; Cardiovascular Diseases; Diagnostic Techni | 2011 |
[New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system].
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardiovascular System; Heart Rate; Humans; Mor | 2006 |
5 trials available for urea and Myocardial Ischemia
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Chi-Square Distribution; Coronary Angiography; Double- | 2013 |
Dose-finding study of landiolol hydrochloride: a short-acting β1-blocker for controlling heart rate during coronary computed-tomography angiography in Japan.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Artifacts; Blood Pressure; Coronary Angiography; Dose- | 2013 |
A multicenter, open-label study of an intravenous short-acting β1-adrenergic receptor antagonist landiolol hydrochloride for coronary computed tomography angiography by 16-slice multi-detector computed tomography in Japanese patients with suspected ischem
Topics: Adrenergic beta-Antagonists; Aged; Coronary Angiography; Female; Heart Rate; Humans; Injections, Int | 2014 |
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angina Pectoris; Dose-Response Relationship, D | 2015 |
Myocardial metabolism assessed by microdialysis: a prospective randomized study in on- and off-pump coronary bypass surgery.
Topics: Aged; Biomarkers; Coronary Artery Bypass, Off-Pump; Energy Metabolism; Female; Glucose; Glycerol; Hu | 2010 |
12 other studies available for urea and Myocardial Ischemia
| Article | Year |
|---|---|
Combined Therapy With Dobutamine and Omecamtiv Mecarbil in Pigs With Ischemic Acute Heart Failure Is Attributed to the Effect of Dobutamine.
Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Drug | 2020 |
Stimulation of Structural and Functional Recovery of the Kidney in Rats with Postischemic Acute Renal Failure of Different Severity by Embryonic Protein-Peptide Complex Therapy.
Topics: Acute Kidney Injury; Animals; Creatinine; Kidney; Male; Myocardial Ischemia; Rats; Regenerative Medi | 2020 |
Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure.
Topics: Animals; Cardiotonic Agents; Cardiovascular Agents; Diastole; Dobutamine; Drug Therapy, Combination; | 2018 |
Radiation-Dose-Lowering Effects of Landiolol Hydrochloride in Coronary Angiography Using Computed Tomography (DELIGHT) - A Prospective Multicenter Study.
Topics: Blood Pressure; Coronary Angiography; Heart Rate; Humans; Morpholines; Myocardial Ischemia; Prospect | 2016 |
Soluble epoxide hydrolase inhibitors might prevent ischemic arrhythmias via microRNA-1 repression in primary neonatal mouse ventricular myocytes.
Topics: Animals; Animals, Newborn; Arrhythmias, Cardiac; Benzoates; Cell Survival; Cells, Cultured; Connexin | 2017 |
Successful treatment with landiolol for the recurrence of significant ST-segment depression during early postoperative period.
Topics: Anti-Arrhythmia Agents; Endarterectomy, Carotid; Humans; Male; Middle Aged; Morpholines; Myocardial | 2008 |
The profile and prognosis of patients hospitalised with heart failure. The value of discharge blood pressure amd cholesterol.
Topics: Age Factors; Aged; Blood Pressure; Cholesterol; Chronic Disease; Creatinine; Female; Heart Failure; | 2008 |
[Role of endogenous intoxication in development of involutive and pathologic processes in patients of elderly and senile age with ischemic heart disease].
Topics: Aged; Aged, 80 and over; Aging; Blood Glucose; Female; Humans; L-Lactate Dehydrogenase; Male; Myocar | 2010 |
[Landiolol prevented myocardial ischemia in a patient with severe aortic stenosis undergoing total gastrectomy].
Topics: Adrenergic beta-Antagonists; Aged; Aortic Valve Stenosis; Gastrectomy; Humans; Male; Morpholines; My | 2007 |
Landiolol has cardioprotective effects against reperfusion injury in the rat heart via the PKCepsilon signaling pathway.
Topics: Adrenergic beta-Antagonists; Alkaloids; Animals; Benzophenanthridines; Cardiotonic Agents; Glyburide | 2007 |
Clinical role and efficacy of landiolol in the intensive care unit.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Blood Pressure; Catecholamines; Female; Hear | 2008 |
Risk factors for ischaemic heart disease and stroke mortality in young and old hypertensive patients.
Topics: Adult; Age Distribution; Aged; Cerebrovascular Disorders; Cholesterol; Female; Humans; Hypertension; | 1995 |